Alberta at BIO International 2025
BioAlberta is heading to BIO International
BioAlberta is proud to lead the Alberta delegation to the BIO International Convention in Boston, MA on June 16 – 19, 2025. We’re excited to showcase Alberta’s thriving life sciences sector on the world stage. With innovative companies, cutting-edge research, and a collaborative network of industry leaders, we’re ready to demonstrate the strength and potential of our ecosystem.
Thank you to our Amazing Sponsors
Special thanks to:
Support Alberta’s Life Sciences Sector
We offer exciting sponsorship opportunities for organizations looking to connect with key players in Alberta’s thriving life sciences industry.
Events Hosted by BioAlberta at BIO International 2025
Alberta Delegation
Click below to view the delegates representing Alberta at BIO International 2025
48Hour Discovery
48Hour Discovery (48HD) is a biotechnology company accelerating peptide drug discovery through its proprietary phage display platform. Founded in 2017 and headquartered in Edmonton, Alberta, 48HD combines high-throughput screening, state-of-the-art chemical modification, and AI-driven analysis to rapidly identify and optimize macrocyclic peptides for therapeutic and diagnostic use.
The platform enables partners to move quickly from hit to optimized lead, supporting applications across oncology, immunology, and radiopharmaceutical development. With a growing portfolio of preclinical-stage binders to high-value targets, 48HD is helping redefine what’s possible in early-stage drug discovery.
Backed by strategic collaborations with over 25 pharmaceutical and biotech companies—including several global leaders—48HD offers both service-based discovery and co-development opportunities to advance peptide therapeutics and theranostics. Recent innovations include late-stage peptide reshaping technologies that enable post-selection chemical tuning to enhance binding, stability, and functionalization.
Ask us about our portfolio of potent binders to tumor-relevant cancer targets—and how Canadian innovation is driving the next generation of precision medicines.
AbbVie
Alberta Innovates
Alberta innovates is the province’s most comprehensive research and innovation agency. From funding to commercialization, we are Alberta’s innovation engine. We foster and accelerate research and innovation to benefit citizens and drive economic growth.
Alberta Innovates works across sectors to fund, partner and enable entrepreneurship throughout the province. The corporation operates in 11 locations with more than one million sq ft of industrial testing and lab facilities. Alberta Innovates employs 589 highly skilled scientists, business and technical professionals.
Our focus on health research and technology innovation aims to transform care, providing Albertans with the services they need, where and when they need them. Alberta Innovates manages a collaborative province-wide initiative – Clinical Trials Alberta – aimed at building capacity and capabilities in our clinical trial ecosystem. Clinical Trials Alberta works with our research community, trial sponsors, and healthcare providers to ensure we respond to the needs of industry as an attractive destination for conducting high-quality clinical trials.
We exist to serve Albertans, empower our partners and inspire future innovators to build a better, healthier future.
Learn how Alberta Innovates.
Alberta Real World Evidence Consortium
Alberta Real World Evidence Consortium
The province of Alberta stands out as a global leader in real-world health system data, housing one of Canada’s largest, most mature, and comprehensive repositories. This remarkable resource serves as the foundation for the Alberta Real World Evidence Consortium, a highly experienced cross-functional provincial research team from the Universities of Alberta and Calgary, along with the Institute of Health Economics. Leveraging these unique data assets, the Consortium conducts timely health-focused research using real-world data, engaging funding partners, decision-makers, and knowledge users.
The Consortium initiates the collaborative research process by considering the interests of our funding partners, and aligning these with our deep understanding of the evidence required to support health care and drug policy decision-making. By doing so, we identify the right research questions and generate meaningful evidence from a trusted source that can be used for informed decision-making.
Business objectives
The Alberta Real World Evidence Consortium provides businesses in the health care sector the opportunity to support collaborative real-world data-driven research that generates meaningful evidence from a trusted source, providing invaluable insights that contribute to advancing health outcomes and supporting the shaping of effective policies and decisions.
Applied Pharmaceutical Innovation (API)
API, one of Canada’s largest not-for-profit life sciences organizations, bridges the gap between academic research, development and commercialization. Enabling innovation among life sciences academia, startups and small to medium-sized enterprises, API provides direct access to industry capacity and expertise, accelerating testing and development timelines. With a comprehensive suite of services, API serves as a COMO, CRO, scientific and commercialization one-stop solution for pharmaceuticals, natural health products, medical devices and diagnostics companies.
API has grown to more than 70 staff and is supported by an interdisciplinary external network of over 100 scientists, clinicians, regulatory, patent and market experts. API has attracted over 75 industry-led projects, created more than $500M in value for incubated companies and supported over 50 SMEs, scale-ups, and spinoffs.
Based in Alberta with lab and office spaces in Edmonton and Calgary, API works with partners across Canada and around the world to build life sciences companies and expand expertise for students, postdoctoral fellows and entrepreneurs. Further, API is building new capacity to bolster critical medicine supply chains, emphasizing readiness for global health emergencies through initiatives like commercial-scale manufacturing and novel compound discovery platforms.
BioAlberta
OUR MISSION
BioAlberta is the voice and champion for the life sciences and health innovation industry in Alberta. We promote, advocate and proactively facilitate the growth of Alberta’s life sciences industry.
OUR VISION
A thriving and competitive life sciences industry that fuels key sectors of Alberta’s economy.
OUR VALUES
At BioAlberta we:
- Advocate for industry by engaging sector companies and organizations to create a coordinated voice to policy makers, key stakeholders, and the public;
- Provide thought leadership and industry commentary that articulates the value of life sciences and the role of science, research and development as an economic driver;
- Establish strategic alliances that provide collaboration and growth opportunities for members;
- Provide members with increased value through opportunities to engage, collaborate and support each other;
CaRe Clinics
WHO WE ARE
CaRe Clinic research staff have a combined experience of hundreds of clinical trials and have become one of Canada’s most respected clinical research centres.
WHAT WE DO
We partner together with academic centres and pharmaceutical companies to help make new treatments available for patients. Our core research areas include: women’s health, dermatology, general medicine, vaccines, infectious diseases, migraine treatments and more.
Entos Pharmaceuticals
About Entos Pharmaceuticals Inc
A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. Since its inception in 2016, Entos® has been dedicated to advancing next-generation genetic medicines using our proprietary Fusogenix™ PLV™ drug delivery system. The Fusogenix PLV platform is formulated with FAST proteins to enable the delivery of nucleic acid to target cells through direct fusion. Entos is pioneering the development of life-changing medicines for patients and has partnered with global companies, such as Eli Lilly, to accelerate and expand the impact of our platform. Entos Pharmaceuticals Inc. is headquartered in Edmonton, Canada, with its wholly owned U.S. and U.K. subsidiaries based in San Diego, California, and London, United Kingdom, respectively. For more information, visit www.entospharma.com, or follow Entos on LinkedIn.
Entos® word mark and design logo, FusogenixTM and PLVTM are registered trademarks of Entos Pharmaceuticals Inc. All other trademarks and registered trademarks are the property of their respective owners.
GlycoNet
GlycoNet is a pan-Canadian research and commercialization network consisting of over 210 researchers in 36 institutions across the country. GlycoNet investigators use the study of carbohydrates (sugars) in living cells to find solutions to unmet health needs through the development of tools, drugs, vaccines and diagnostics. Taking a One-Health approach that considers the connections among human, animal and environmental health, GlycoNet is advancing research, innovation and training in glycomics to improve quality of life for Canadians. Under the network, GlycoNet Integrated Services (GIS) operates as a national platform of glycomics services. GlycoNet and GIS together provide one-stop access to glycomics tools, specialized expertise, consulting and collaborative opportunities to academia and industry, both nationally and internationally. GlycoNet is also a leader in training the next generation of glyco-scientists and promoting collaboration and advancement in glycomics research.
Opportunities for partnering with GlycoNet include:
- Co-funding of research projects in collaboration with GlycoNet investigators
- Access to specialized glycomics services and facilities for clients
- Internships and training opportunities with researchers and industry partners
- Other collaboration and licencing opportunities.
GlycoNet and GIS are supported in part through the Government of Canada’s Strategic Science Fund and the Canada Foundation for Innovation. Learn more: glyconet.ca
Innovative Medicines Canada
Innovative Medicines Canada represents Canada’s innovative pharmaceutical industry. We help our members discover, develop and deliver innovative medicines and vaccines.
Our member companies, which range from early-stage startups to established organizations, are revolutionizing healthcare through the discovery and development of new medicines and vaccines.
Our industry supports 103,000 high-quality, well-paying jobs in Canada and invests $3 billion in R&D every year. Collectively, our activities contribute $16 billion per year to Canada’s knowledge-based economy.
Guided by a strict Code of Ethical Practices, we work with governments, insurance companies, healthcare professionals and other stakeholders to advance the field of pharmaceutical research and development and enhance the wellbeing of Canadians. We are committed to being valued partners in Canada’s healthcare system.
We achieve our goals by forming alliances, supporting policies, improving Canada’s regulatory environment, widening access to innovative medicines and ensuring the effective protection of intellectual property.
We believe in ensuring that Canadians have access to the innovative treatments they need. Our activities are a fundamental part of safeguarding our healthcare system for future generations.
For more information: https://innovativemedicines.ca/about/
Medlior Health Outcomes Research Ltd
Medlior Health Outcomes Research Ltd. is a Canadian research consultancy specializing in real-world evidence (RWE) generation to support healthcare decision-making across the product lifecycle. Since 2008, Medlior has partnered with pharmaceutical, biotech, and MedTech companies to inform market access strategies, demonstrate value, and support regulatory and HTA submissions.
With unique access to Alberta’s comprehensive health system data and a robust network of clinical and academic collaborators, Medlior delivers end-to-end RWE services—from study design and data access to advanced analysis and reporting. Our multidisciplinary team includes experts in epidemiology, biostatistics, health economics, and clinical research.
In addition to evidence generation, Medlior offers strategic market access support through landscape assessments and value proposition development to drive adoption and payer engagement.
We are committed to innovation through methodologically rigorous, AI-enabled evidence generation that accelerate timelines while ensuring scientific integrity. As an independent research organization and trusted partner to industry, government, and health authorities, Medlior delivers insights that matter.
Learn more at: www.medlior.com
My Viva
My Viva Plan is transforming healthcare through an AI-powered digital platform that makes lifestyle medicine scalable, personalized, and effective. Designed for both clinicians and patients, the platform helps prevent and manage chronic conditions like obesity, diabetes, and heart disease.
Clinicians benefit from automated care plans tailored to each patient’s medical profile, streamlined onboarding, and reimbursement-ready reports that reduce administrative burden. Patients receive structured, easy-to-follow plans across physical health, nutrition, and mental well-being, supported by an intuitive app and AI-powered health coach for motivation and habit-tracking.
We serve a wide range of communities—from clinics in Alberta and Ontario to major U.S. health systems, national organizations, and corporate wellness programs. Our partnerships with dietitians, psychologists, and fitness experts ensure holistic, evidence-based care.
Our in-person “Living Lab” clinic in Edmonton enables continuous product testing and improvement, keeping the platform grounded in real-world patient outcomes.
With a mission to make preventive, personalized wellness accessible to all, we bridge the gap between clinical care and patient self-management. The result is a sustainable, data-driven healthcare model that improves outcomes, reduces system strain, and empowers individuals to take control of their health.
Northern Alberta Clinical Trials and Research Centre
University of Alberta
Company Profile – University of Alberta
The University of Alberta in Edmonton is a leading Canadian teaching and research institution, renowned globally for its excellence in humanities, sciences, arts, business, engineering, and health sciences. It is recognized for innovations in energy, AI discoveries, lifesaving vaccines, cell-based therapies, Indigenous research, agricultural advancements, and studies on intersectional inequities and decolonization.
Improving lives. Changing lives. Saving lives. The U of A is a catalyst in creating incredible growth in research — accelerating data and discoveries with promise to solve some of the most pervasive health care problems of our time.
University of Calgary
UCalgary researchers are partnering with industry sponsors to turn knowledge into breakthrough treatments, diagnostics, devices and solutions. Our scholars have made significant progress in bridging the gap between research results and practical application of knowledge.
Our Goals for BIO
- Research Partnerships with global SMEs, MNEs.
- Collaborations with international academic partners.
- Collaborations with international governmental partners, trade commissions.
- Outreach on capabilities and institutes at University of Calgary.
- Investor relationships for UCeed.
- Out licensing of University Created IP.
